thumb
May 9, 2022

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE  UNDER THE ACCELERATED APPROVAL PATHWAY

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has completed the rolling submission to the U.S.

thumb
February 18, 2022

Biogen to Present at the Cowen 42nd Annual Health Care Conference

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that it will present at the Cowen 42nd Annual Health Care Conference. The webcast will be live on Monday, March 7, 2022, at 9:50 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at

thumb
February 16, 2022

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms Key secondary endpoint demonstrates zuranolone co-initiated with an antidepressant was statistically significant in reducing

thumb
February 7, 2022

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savings CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have

thumb
February 3, 2022

Biogen Reports Fourth Quarter and Full Year 2021 Results

Cambridge, Mass., February 3, 2022 -- Biogen Inc. (Nasdaq: BIIB) today reported fourth quarter and full year 2021 financial results. “Biogen continued to execute well in the fourth quarter despite the challenges we have faced,” said Michel Vounatsos, Biogen's Chief Executive Officer.

thumb
February 1, 2022

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to

thumb
January 31, 2022

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen’s Board of Directors, effective at the time of the Company’s 2022 annual meeting of stockholders. Ms.

thumb
January 27, 2022

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

The companies will continue with their exclusive agreements, including for commercialization of their current portfolio CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire

thumb
January 27, 2022

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM ®  (aducanumab-avwa) 100 mg/mL injection for intravenous use in early

thumb
January 19, 2022

Biogen to Report Fourth Quarter and Full Year 2021 Financial Results February 3, 2022

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2021 financial results Thursday, February 3, 2022, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00

thumb
January 11, 2022

Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

Alzheimer’s patients and their families deserve to have choice and access to FDA-approved treatments. Biogen believes that the proposed coverage with evidence development (CED) decision for anti-amyloid therapies denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100